Key facts
- This page summarizes Paradigm Biocapital Advisors LP's Form 4 filing for Olema Pharmaceuticals, Inc. (OLMA).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 08 Dec 2023, 16:19.
Paradigm Biocapital Advisors LP - 06 Dec 2023 Form 4 Insider Report for Olema Pharmaceuticals, Inc. (OLMA)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- OLMA
- Reported as of
- 06 Dec 2023
- Net transaction value
- +$1,160,000
- SEC form
- 4
- Accepted by SEC
- 08 Dec 2023, 16:19:27 UTC
- Prior SEC filing
- 21 Sep 2023
- Next SEC filing
- 05 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Kim, as an authorized signatory of the Fund and the Adviser GP (for itself and on behalf of the Adviser)
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Paradigm Biocapital Advisors LP filed Form 4 for Olema Pharmaceuticals, Inc. (OLMA) on 08 Dec 2023.
Change
- Previous filing in this sequence was filed on 21 Sep 2023.
- Current net transaction value: +$1,160,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
OLMA
transaction
Common Stock, par value $0.0001 per share
Purchase
- Transaction value
- $1,160,000
- Shares
- +100,000
- Change %
- +1.5%
- Price
- $11.60
- Shares after
- 6,590,981
- Date
- 06 Dec 2023
- Ownership
- By: Paradigm BioCapital International Fund Ltd.
- Footnotes
- F1
OLMA
holding
Common Stock, par value $0.0001 per share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,312,619
- Date
- 06 Dec 2023
- Ownership
- By: One or more separately managed accounts
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These securities are held directly by Paradigm BioCapital International Fund Ltd (the "Fund"). The Fund is a private investment vehicle. Paradigm BioCapital Advisors LP (the "Adviser") is the investment adviser of the Fund. Paradigm BioCapital Advisors GP LLC (the "Adviser GP") is the general partner of the Adviser. Senai Asefaw, M.D. is the managing member of the Adviser GP. Each Reporting Person disclaims beneficial ownership of all securities reported herein, except to the extent of their pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities and Exchange Act of 1934 or for any other purpose.
Footnote F2
These securities are held directly by one or more separately managed accounts managed by the Adviser. Each Reporting Person disclaims beneficial ownership of all securities reported herein, except to the extent of their pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities and Exchange Act of 1934 or for any other purpose.